Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31609333 | 1.00 | IDO1 (0.42) | IDO1TRPM8PIN1CA1CA2 | |
| SCHEMBL5965470 | 1.00 | IDO1 (0.42) | IDO1TRPM8PIN1CA1CA2 | |
| SCHEMBL30481743 | 1.00 | IDO1 (0.42) | IDO1TRPM8PIN1CA1CA2 | |
| Formic Acid SCHEMBL27722671 | 0.94 | TRPM8 (0.39) | IDO1TRPM8PIN1CA1CA2 | |
| SCHEMBL5285710 | 0.90 | HTT (0.48) | IDO1TRPM8TSHRHTT | |
| SCHEMBL30644032 | 0.90 | HTT (0.48) | IDO1TRPM8TSHRHTT | |
| SCHEMBL5158911 | 0.83 | MTNR1A (0.44) | IDO1TRPM8PIN1TSHRNPSR1 | |
| SCHEMBL14957322 | 0.83 | GRM2 (0.40) | DPP8 | |
| SCHEMBL31072340 | 0.83 | MTNR1A (0.44) | IDO1TRPM8PIN1TSHRNPSR1 | |
| SCHEMBL8796201 | 0.80 | ECE1 (0.44) | TRPM8PIN1TSHRNPSR1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 801 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-06-26 | — | — | US | claimed |
| EP-4493273-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | Politechnika Wroclawska (PL) | 2025-01-22 | — | — | EP | claimed |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | SIXTH STREET LENDING PARTNERS | 2024-03-07 | — | — | US | claimed |
| WO-2023175356-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | POLITECHNIKA WROCLAWSKA (PL) | 2023-09-21 | — | — | WO | claimed |
| US-11661441-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | claimed |
| EP-4105224-A1 | LONG-ACTING COMPSTATIN ANALOGS AND USES THEREOF | Apellis Pharmaceuticals, Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| CN-105582523-B | Compstatin and analogs thereof for ocular disorders | 阿佩利斯制药公司 | 2022-04-15 | — | — | CN | claimed |
| EP-2707384-B1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | claimed |
| CN-107050422-B | Cell-reactive, long-acting or targeted compstatin analogs and uses thereof | 阿佩利斯制药公司 | 2021-11-09 | — | — | CN | claimed |
| WO-2019179985-A1 | INHIBITORS OF MINT AND USES THEREOF | UNIVERSITY OF COPENHAGEN (DK) | 2019-09-26 | — | — | WO | claimed |
| WO-2012107244-A1 | PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS | ORGANOBALANCE GMBH (DE) | 2012-08-16 | — | — | WO | claimed |
| US-20120040915-A1 | PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | claimed |
| WO-2010088527-A2 | PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2010-08-05 | — | — | WO | claimed |
| US-6991775-B2 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. (US) | 2006-01-31 | — | — | US | claimed |
| EP-0813544-B1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH INC (US) | 2004-10-27 | — | — | EP | claimed |
| EP-0813544-A4 | — | — | 1998-01-07 | — | — | EP | claimed |
| EP-0813544-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1997-12-29 | — | — | EP | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-5610140-A | ANALGESICS, ANTIINFLAMMTORY AGENTS; TREATMENT OF ASTHMA | CORTECH, INC. (US) | 1997-03-11 | — | — | US | claimed |
| WO-1995024422-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1995-09-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661441-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | C3AR1, C5AR1, SERPINC1 | IDO1 1531/4885TRPM8 4518/4885PIN1 2331/4885 |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | C3AR1, C5AR1, SERPINC1 | IDO1 1531/4885TRPM8 4518/4885PIN1 2331/4885 |
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | F11, F2, F12 | IDO1 2965/4885TRPM8 3669/4885PIN1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.